Abstract
Psoriasis is a chronic immune-mediated inflammatory systemic disease that mainly affects skin. Secukinumab is an anti-interleukin-17A agent approved for the treatment of moderate-to-severe psoriasis that has probed efficacy and safety both in clinical trials and in real-world practice. Secukinumab data sheet dose approved in maintenance response phase for adults with psoriasis is 300mg monthly. Recently, dose optimization for biologic therapies in psoriasis has been proposed in order to individualise the treatment looking for better treatment adherence and better cost-effectiveness due to their high costs. In this scenario, we report our real-world experience in dose optimization for patients with moderate-to-severe psoriasis treated with Secukinumab.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
